SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Amendment No. 4
Under the Securities Exchange Act of 1934
La Jolla Pharmaceutical Company
-------------------------------
(Name of Issuer)
Common Stock
------------------------------
(Title of Class of Securities)
503459109
--------------
(CUSIP Number)
Hilary Strain
One Embarcadero Center, Suite 4050
San Francisco, CA 94111
(415) 362-4022
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
December 29, 2004
-----------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]
Check the following box if a fee is being paid with this statement: (A
fee is not required only if the reporting person: (1) has a previous statement
on file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.
(See Rule 13d-7).
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom copies
are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act") or otherwise subject to the
liabilities of that section of the Exchange Act but shall be subject to all
other provisions of the Exchange Act.
(Continued on following page(s))
Page 1 of 16 Pages
CUSIP NO. 503459109 13 D 2 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alta Partners
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
WC
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
California
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
IA
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 3 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alta BioPharma Partners, L.P.
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
WC
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
PN
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 4 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alta Embarcadero BioPharma Partners, LLC
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
WC
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
California
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
CO
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 5 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
La Jolla Chase Partners (Alta Bio), LLC
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
WC
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Deleware
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
CO
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 6 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alta BioPharma Management, LLC
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
WC
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Deleware
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
CO
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 7 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alta/Chase BioPharma Management, LLC
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
WC
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Deleware
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451 EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
CO
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 8 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Jean Deleage
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
AF
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451 EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
IN
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 9 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Garrett Gruener
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
AF
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
IN
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 10 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Daniel Janney
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
AF
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451 EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
IN
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 11 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alix Marduel
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
AF
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451 EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
IN
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
CUSIP NO. 503459109 13 D 12 of 16 Pages
------------------------- ----------------------------------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Guy Nohra
------------------------- ----------------------------------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
------------------------- ----------------------------------------------------------------------------------------------------------
(3) SEC USE ONLY
------------------------- ----------------------------------------------------------------------------------------------------------
(4) SOURCE OF FUNDS*
AF
------------------------- ----------------------------------------------------------------------------------------------------------
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
------------------------- ----------------------------------------------------------------------------------------------------------
EXIT FILING
NUMBER OF (7) SOLE VOTING POWER 0
SHARES
BENEFICIALLY ----------------------------------------------------------------------------------------------------------
OWNED BY (8) SHARED VOTING POWER 2,826,451
EACH
REPORTING
PERSON ----------------------------------------------------------------------------------------------------------
WITH (9) SOLE DISPOSITIVE POWER 0
----------------------------------------------------------------------------------------------------------
(10) SHARED DISPOSITIVE POWER 2,826,451
------------------------- ----------------------------------------------------------------------------------------------------------
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,826,451 EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
------------------------- ----------------------------------------------------------------------------------------------------------
(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
4.6% EXIT FILING
------------------------- ----------------------------------------------------------------------------------------------------------
(14) TYPE OF REPORTING PERSON*
IN
------------------------- ----------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1. Security and Issuer.
This Statement on Schedule D relates to the Common Stock, $0.001 par
value per share (the "Shares"), of La Jolla Pharmaceutical Company, a Delaware
corporation (the "Company"). The principal executive offices of the Company are
located at 6455 Nancy Ridge Drive, San Diego, California 92121.
EXIT FILING --- The outstanding shares of La Jolla Pharmaceutical
Company increased to 61,400,323, resulting in the shares held by the funds
affiliated with Alta Partners to drop to 4.6% ownership. See Item 5 (a)
Item 2. Identity and Background.
(a) This Exit Filing is filed by Alta BioPharma Partners, L.P., a
Delaware limited partnership ("Alta BioPharma"), and Alta Embarcadero BioPharma
Partners, LLC, a California limited liability company ("Embarcadero LLC"), and
La Jolla Chase Partners (Alta Bio), LLC, a Delaware LLC ("La Jolla Alta Bio") by
virtue of their direct beneficial ownership of Shares, by Alta BioPharma
Management, LLC, a Delaware limited liability company ("Alta Management"), by
virtue of being the sole general partner of Alta BioPharma, by Alta/Chase
BioPharma Management LLC, a Delaware limited liability company (Alta/Chase
Management) by virtue of being the sole managing director of La Jolla Chase
Partners (Alta Bio), LLC and by Alta Partners, a California corporation ("Alta
Partners"), by virtue of being the management advisory company of these
entities. Alta BioPharma, Embarcadero LLC, La Jolla Alta Bio, Alta Management,
Alta/Chase Management and Alta Partners are collectively referred to as the
"Reporting Persons." Jean Deleage, Garrett Gruener, Dan Janney, Alix Marduel,
and Guy Nohra (the "Partners") are the managing directors of Alta Management,
Alta/Chase Management and officers of Alta Partners. By virtue of the
relationships described above and their roles with Alta Partners, each of the
Partners may be deemed to control Alta Partners, Alta/Chase Management, Alta
Management, and, therefore, may be deemed to possess indirect beneficial
ownership of the Shares held by each entity. However, none of the Partners,
acting alone, has voting or investment power with respect to the Shares directly
beneficially held by the entities and, as a result, the Partners disclaim
beneficial ownership of the Shares directly beneficially owned by each entity,
except to the extent of their pecuniary interest in each entity. Embarcadero LLC
is a side company that makes all investments pro rata to the capital of Alta
BioPharma with all allocations made to its members based on paid-in capital.
Certain of the Partners are members of Embarcadero LLC and certain members of
Embarcadero LLC are affiliates of Alta Partners.
(b) The principal executive offices of Alta BioPharma, Embarcadero LLC,
La Jolla Alta Bio, Alta Management, Alta/Chase Management and Alta Partners, and
the business address of each Partner, are located at One Embarcadero Center,
Suite 4050, San Francisco, California 94111.
(c) Alta Partners provides investment advisory services to several
venture capital funds. Alta BioPharma, La Jolla Alta Bio and Embarcadero LLC's
principal business is acting as venture capital investment vehicles. Alta/Chase
Management and Alta Management's principal business is acting as managing
director of La Jolla Alta Bio and Alta BioPharma, respectively. Each of the
Partners' principal business is acting as a managing director of Alta Management
and Alta/Chase Management and as an officer of Alta Partners.
(d) None of the Reporting Persons or, to the knowledge of the Reporting
Persons, any of the Partners, has been convicted in a criminal proceeding in the
past five years (excluding traffic violations or similar misdemeanors).
13 of 16 Pages
(e) During the past five years, none of the Reporting Persons or, to the
knowledge of the Reporting Persons, none of the Partners, was a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction as a
result of which such person was or is subject to a judgment, decree or final
order enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws of finding any violation with
respect to such laws.
(f) Alta Partners is a California corporation. Alta BioPharma is a
Delaware limited partnership. Embarcadero LLC is a California limited liability
corporation. La Jolla Alta Bio is a Delaware limited liability company. Alta
Management and Alta/Chase Management are Delaware limited liability companies.
Each of the Partners is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration.
N/A Exit Filing The outstanding shares of La Jolla Pharmaceutical
Company increased to 61,400,323, resulting in the shares held by the funds
affiliated with Alta Partners to drop to 4.6% ownership. See Item 5 (a).
Item 4. Purpose of Transaction.
Exit Filing ---- See Item 5 (a)
Item 5. Interest in Securities of the Issuer.
Exit Filing ------ The funds affiliated with Alta Partners beneficially
own 2,826,451 shares or approximately 4.6% of the shares deemed outstanding by
the Company (61,400,323) as of November 30, 2004. Alta BioPharma is the direct
beneficial owner of 1,756,883 shares of Common Stock or approximately 2.86% of
the shares deemed outstanding by the Company (61,400,323) as of November 30,
2004. La Jolla Alta Bio is the direct beneficial owner of 1,003,348 shares of
Common Stock or approximately 1.63% of the shares deemed outstanding by the
Company (61,400,323) as of November 30, 2004. Embarcadero LLC is the direct
beneficial owner of 66,220 shares of Common Stock or approximately 0.11% of the
shares deemed outstanding by the Company (61,400,323) as of November 30, 2004
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
Exit Filing
Item 7. Material to be Filed as Exhibits.
None
14 of 16 Pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: December 29, 2004
Alta Partners Alta BioPharma Partners, L.P.
By: /s/ Jean Deleage By: Alta BioPharma Management, LLC
-------------------- Its General Partner
Jean Deleage, Vice President
Alta BioPharma Management, LLC By: /s/ Daniel Janney
---------------------
Daniel Janney, Managing Director
By: /s/ Jean Deleage La Jolla Chase Partners (Alta Bio), LLC
--------------------
Jean Deleage, Member
By: Alta/Chase BioPharma Management, LLC
Alta/Chase BioPharma Management, LLC Its Managing Member
By: /s/ Daniel Janney By: /s/ Daniel Janney
--------------------- ---------------------
Daniel Janney, Member Daniel Janney, Member
Alta Embarcadero BioPharma Partners, LLC
By: /s/ Jean Deleage
--------------------
Jean Deleage, Member
/s/ Jean Deleage /s/ Guy Nohra
---------------- -------------
Jean Deleage Guy Nohra
/s/ Garrett Gruener /s/ Alix Marduel
------------------- ----------------
Garrett Gruener Alix Marduel
/s/ Daniel Janney
-----------------
Daniel Janney
15 of 16 Pages
EXHIBIT A
Joint Filing Statement
We, the undersigned, hereby express our agreement that the attached
Schedule 13D is filed on behalf of each of us.
Date: December 29, 2004
Alta Partners Alta BioPharma Partners, L.P.
By: /s/ Jean Deleage By: Alta BioPharma Management, LLC
-------------------- Its General Partner
Jean Deleage, Vice President
Alta BioPharma Management, LLC By: /s/ Daniel Janney
---------------------
Daniel Janney, Managing Director
By: /s/ Jean Deleage La Jolla Chase Partners (Alta Bio), LLC
--------------------
Jean Deleage, Member
By: Alta/Chase BioPharma Management, LLC
Alta/Chase BioPharma Management, LLC Its Managing Member
By: /s/ Daniel Janney By: /s/ Daniel Janney
--------------------- ---------------------
Daniel Janney, Member Daniel Janney, Member
Alta Embarcadero BioPharma Partners, LLC
By: /s/ Jean Deleage
--------------------
Jean Deleage, Member
/s/ Jean Deleage /s/ Guy Nohra
---------------- -------------
Jean Deleage Guy Nohra
/s/ Garrett Gruener /s/ Alix Marduel
------------------- ----------------
Garrett Gruener Alix Marduel
/s/ Daniel Janney
-----------------
Daniel Janney
16 of 16 Pages